The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications

Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate...

Full description

Saved in:
Bibliographic Details
Published inQuantitative imaging in medicine and surgery Vol. 8; no. 7; pp. 709 - 718
Main Authors Lim, Wanyin, Ridge, Carole A., Nicholson, Andrew G., Mirsadraee, Saeed
Format Journal Article
LanguageEnglish
Published AME Publishing Company 01.08.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.
AbstractList Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8 th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7 th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7 th edition is further subcategorized into M1b and M1c in the 8 th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8 th edition, as well as discussion on the implications on treatment.
Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.
Author Mirsadraee, Saeed
Nicholson, Andrew G.
Ridge, Carole A.
Lim, Wanyin
Author_xml – sequence: 1
  givenname: Wanyin
  surname: Lim
  fullname: Lim, Wanyin
– sequence: 2
  givenname: Carole A.
  surname: Ridge
  fullname: Ridge, Carole A.
– sequence: 3
  givenname: Andrew G.
  surname: Nicholson
  fullname: Nicholson, Andrew G.
– sequence: 4
  givenname: Saeed
  surname: Mirsadraee
  fullname: Mirsadraee, Saeed
BookMark eNp1kctPAyEQxonR-L575OildRjqPjyYGOMr8XHpnQDLthiWrTtU0_9eqvWgiWQSBub7foF8B2w79tExdiJgjAJkefbmOxojiGoMuXCL7SOiHE0kFNs_Pda4x46JXiGvshKlgF22JwHFGrHPaDp3vEpzHpZxxq2O1g18-vzEbdBEvvVWJ99HrmOTr3zM58Ap6ZnPclpRct0FH9y7dx-8b3nKNDvXcebot8V3i7Bh0RHbaXUgd7zZD9n09mZ6fT96fLl7uL56HFlZ1GlktWhlWQAa20hrJtgYiQDFxOjaSIOtlqbM80ktGpS1BWeLptJN7UxlhZaH7PIbu1iazjXWxTTooBaD7_SwUr326vck-rma9e-qEFieI2TA6QYw9G9LR0l1nqwLQUfXL0mtUyhKhHORpcW31A490eBaZX36-m0m-6AEfKlLtc5MrTNTkAuzEf4Yf973r-UTcImdzA
CitedBy_id crossref_primary_10_1053_j_semnuclmed_2022_04_011
crossref_primary_10_1016_j_jtho_2023_08_011
crossref_primary_10_1016_j_thorsurg_2021_07_010
crossref_primary_10_1016_j_rmcr_2020_101074
crossref_primary_10_1186_s43168_022_00133_x
crossref_primary_10_1002_cam4_4560
crossref_primary_10_1186_s13014_021_01904_4
crossref_primary_10_1186_s12885_022_10333_9
crossref_primary_10_3390_cancers14235994
crossref_primary_10_1002_jcla_24412
crossref_primary_10_1016_j_cllc_2022_02_002
crossref_primary_10_1042_BSR20203097
crossref_primary_10_12729_jbtr_2024_25_4_221
crossref_primary_10_3390_curroncol28030157
crossref_primary_10_1245_s10434_024_15762_3
crossref_primary_10_1080_02656736_2021_1902000
crossref_primary_10_3390_cancers16030506
crossref_primary_10_1136_bmjopen_2021_057638
crossref_primary_10_1007_s00117_022_01102_7
crossref_primary_10_2217_fon_2022_1216
crossref_primary_10_3892_ol_2022_13558
crossref_primary_10_1097_MNM_0000000000001367
crossref_primary_10_2217_epi_2020_0399
crossref_primary_10_3389_fmed_2021_680679
crossref_primary_10_1016_j_jtcvs_2024_10_053
crossref_primary_10_3390_medicina57040393
crossref_primary_10_1089_jayao_2021_0069
crossref_primary_10_1016_j_jvir_2021_05_006
crossref_primary_10_1183_16000617_0174_2022
crossref_primary_10_1016_j_heliyon_2023_e16865
crossref_primary_10_1515_iss_2020_0010
crossref_primary_10_1007_s11306_022_01918_3
crossref_primary_10_1055_a_1714_1941
crossref_primary_10_2967_jnmt_124_267843
crossref_primary_10_1016_j_remnie_2020_09_012
crossref_primary_10_1186_s12967_020_02606_3
crossref_primary_10_1177_15330338221133222
crossref_primary_10_1016_j_jmig_2021_07_023
crossref_primary_10_1016_j_clinimag_2020_11_048
crossref_primary_10_1080_02656736_2021_1914353
crossref_primary_10_3389_fonc_2023_1117348
crossref_primary_10_1080_02656736_2021_1885755
crossref_primary_10_1097_CCO_0000000000001005
crossref_primary_10_1155_2021_1436088
crossref_primary_10_3389_fonc_2021_643261
crossref_primary_10_1007_s00330_021_07865_2
crossref_primary_10_1016_j_jtho_2023_09_277
crossref_primary_10_1093_jjco_hyac204
crossref_primary_10_1093_icvts_ivab209
crossref_primary_10_18794_aams_163055
crossref_primary_10_3390_biomedinformatics4040129
crossref_primary_10_1007_s12149_021_01694_5
crossref_primary_10_3892_mmr_2021_12227
crossref_primary_10_1186_s12885_022_09908_3
crossref_primary_10_4103_ijnm_IJNM_170_20
crossref_primary_10_1186_s12885_024_13268_5
crossref_primary_10_21294_1814_4861_2020_19_4_105_111
crossref_primary_10_1002_cam4_4990
crossref_primary_10_1055_a_1517_8525
crossref_primary_10_1111_1759_7714_13129
crossref_primary_10_17116_hirurgia202212120
crossref_primary_10_1016_j_resmer_2022_100887
crossref_primary_10_1177_15330338211039676
crossref_primary_10_1016_j_lungcan_2020_10_004
crossref_primary_10_1016_j_remn_2020_06_025
crossref_primary_10_4103_aca_aca_132_22
crossref_primary_10_2217_imt_2019_0105
crossref_primary_10_3892_ol_2024_14637
crossref_primary_10_7759_cureus_80200
crossref_primary_10_3322_caac_21785
crossref_primary_10_1155_2022_6619331
crossref_primary_10_3892_ol_2021_13155
crossref_primary_10_1016_j_intimp_2022_109391
crossref_primary_10_7717_peerj_16923
crossref_primary_10_1186_s13019_023_02380_5
crossref_primary_10_3390_ijms22168885
crossref_primary_10_1136_bmjopen_2021_052556
crossref_primary_10_1186_s11658_024_00636_z
crossref_primary_10_1155_2022_5698582
crossref_primary_10_1016_j_lungcan_2024_107471
crossref_primary_10_1097_RLU_0000000000003903
crossref_primary_10_3390_jcm13154570
crossref_primary_10_1016_j_clon_2021_07_008
crossref_primary_10_2217_bmm_2019_0583
crossref_primary_10_5582_ddt_2019_01032
crossref_primary_10_3389_fonc_2021_696732
crossref_primary_10_1002_ima_22858
crossref_primary_10_1016_j_ijscr_2020_03_021
crossref_primary_10_2147_OTT_S243221
crossref_primary_10_18632_aging_205183
crossref_primary_10_3390_jcm13051450
crossref_primary_10_1111_1759_7714_13213
crossref_primary_10_2147_CMAR_S254139
crossref_primary_10_3389_fonc_2022_881015
crossref_primary_10_1111_1759_7714_15253
crossref_primary_10_21641_los_2020_17_4_190
crossref_primary_10_1080_02656736_2021_1976852
crossref_primary_10_1200_GO_21_00100
crossref_primary_10_1007_s12149_022_01795_9
crossref_primary_10_3904_kjim_2021_488
crossref_primary_10_1016_j_chest_2023_11_042
crossref_primary_10_2147_JIR_S402108
crossref_primary_10_3389_fonc_2022_942964
crossref_primary_10_1016_j_lungcan_2024_107868
crossref_primary_10_1016_j_mpdhp_2022_08_004
crossref_primary_10_1093_hropen_hoab025
crossref_primary_10_1097_MD_0000000000028617
crossref_primary_10_1097_MD_0000000000025748
crossref_primary_10_1111_1759_7714_13861
crossref_primary_10_1038_s41419_024_07129_z
crossref_primary_10_1177_10760296231159121
crossref_primary_10_1186_s13019_024_02922_5
crossref_primary_10_3389_fcell_2021_797984
crossref_primary_10_2174_0118743064318977240531100045
crossref_primary_10_1016_j_heliyon_2024_e36881
crossref_primary_10_2214_AJR_20_23025
crossref_primary_10_1002_cam4_3055
crossref_primary_10_1016_j_jtocrr_2021_100165
crossref_primary_10_1186_s12911_022_01975_7
crossref_primary_10_3390_cancers16091655
crossref_primary_10_1097_COC_0000000000000828
crossref_primary_10_7759_cureus_17992
crossref_primary_10_1016_j_heliyon_2023_e17969
crossref_primary_10_1111_1759_7714_13711
crossref_primary_10_52054_FVVO_13_3_025
crossref_primary_10_1142_S0192415X22500847
crossref_primary_10_3390_cancers15102855
crossref_primary_10_1016_j_jtcvs_2023_09_048
crossref_primary_10_1097_RLU_0000000000004295
crossref_primary_10_1097_MD_0000000000034184
crossref_primary_10_18632_aging_204112
crossref_primary_10_1016_j_intimp_2023_111147
crossref_primary_10_1007_s11604_022_01366_y
crossref_primary_10_1016_j_bbrep_2024_101833
crossref_primary_10_1016_j_ejrad_2021_109718
crossref_primary_10_1016_j_suronc_2020_12_008
crossref_primary_10_1111_1754_9485_13720
crossref_primary_10_1155_2019_2901840
crossref_primary_10_3389_fonc_2022_933278
crossref_primary_10_5306_wjco_v15_i6_755
crossref_primary_10_1007_s13246_021_00988_2
crossref_primary_10_3390_diagnostics11030425
crossref_primary_10_1038_s41598_024_66307_3
crossref_primary_10_1097_COC_0000000000001116
crossref_primary_10_1002_cam4_7024
crossref_primary_10_1016_j_celrep_2021_109905
crossref_primary_10_1245_s10434_020_09151_9
crossref_primary_10_1177_00033197231213197
crossref_primary_10_1186_s12890_021_01817_8
crossref_primary_10_4103_ecdt_ecdt_54_23
crossref_primary_10_1002_ccr3_6859
crossref_primary_10_3233_CBM_182333
crossref_primary_10_18332_pne_161745
ContentType Journal Article
Copyright 2018 Quantitative Imaging in Medicine and Surgery. All rights reserved. 2018 Quantitative Imaging in Medicine and Surgery.
Copyright_xml – notice: 2018 Quantitative Imaging in Medicine and Surgery. All rights reserved. 2018 Quantitative Imaging in Medicine and Surgery.
DBID AAYXX
CITATION
7X8
5PM
DOI 10.21037/qims.2018.08.02
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2223-4306
EndPage 718
ExternalDocumentID PMC6127520
10_21037_qims_2018_08_02
GroupedDBID 53G
AAKDD
AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
DIK
HYE
OK1
RPM
7X8
5PM
ID FETCH-LOGICAL-c369t-ca1f37602bcd3cb42db320064ba9b3b2fa3b7760491d239c0ec6d8ad9eb8c1a3
ISSN 2223-4292
IngestDate Thu Aug 21 14:05:59 EDT 2025
Fri Jul 11 01:08:27 EDT 2025
Tue Jul 01 02:30:29 EDT 2025
Thu Apr 24 23:13:18 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c369t-ca1f37602bcd3cb42db320064ba9b3b2fa3b7760491d239c0ec6d8ad9eb8c1a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://qims.amegroups.com/article/viewFile/20898/20517
PMID 30211037
PQID 2103672051
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6127520
proquest_miscellaneous_2103672051
crossref_citationtrail_10_21037_qims_2018_08_02
crossref_primary_10_21037_qims_2018_08_02
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-8-00
20180801
PublicationDateYYYYMMDD 2018-08-01
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-8-00
PublicationDecade 2010
PublicationTitle Quantitative imaging in medicine and surgery
PublicationYear 2018
Publisher AME Publishing Company
Publisher_xml – name: AME Publishing Company
SSID ssj0000781710
Score 2.492246
SecondaryResourceType review_article
Snippet Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 709
SubjectTerms Review
Title The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
URI https://www.proquest.com/docview/2103672051
https://pubmed.ncbi.nlm.nih.gov/PMC6127520
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvZVeW3dBgLyN4jWXHlvc2RksZTcbAZXkzkixTQ-t0sf3Q_fqdI_kib2N0e3GCL3LQ9-XoSDrfOYS85UtRSCWYB2O59EIuAo8nPPDCAutww4ihY1QjrzfR6Xn4ebvazmY3TtRS28j36scfdSX_gyqcA1xRJfsPyA6Nwgn4DvjCERCG460x5s3F4rJF5Szit1-km_VCoUuMMUAWXSNdGxSQja1LZFM444LAqF5BJ9QqgevpQ6UTd-66s19bURmVGsYflVe25bIaduxNK7WjvMbQH1u_-RtYoXKUofU13k0Aih5XWIGpYJ87WZiNvhzLga3LfS3yveiS_cNn7q5i-HyIoeuMHbopHpbOci0zdwgYO1Y2NhkVfrP-rEsg8L28wkTsPjfJWdk40vW7-5sv2cn52VmWHm_TO-QugxlG4Cz0mEE85n5sclkMv8xucpuXHP3yiqlTM85UpnG2juOSPiCH3YyDfrT0eUhmunpE7q07hB6TGlhEgUUUWUQtiyiwiE5ZRAFK2hOCdiyilkUfqOUQ3RUUOEQ7Dk0fcTn0hKQnx-mnU68rxeGpIEoaTwm_wPApJlUeKBmyXAa4GBVKkchAskIEMobrYeLn8CdXS62inIs80ZIrXwRPyUG1q_QzQmPh57lizJcrHa4CKWHKjTn4YNruFzqRc3LUd2WmujT1WC3lMoPpqun8DDs_w87PsIIqm5N3wxPXNkXLX-5906OTgR3FzTFR6V1bm9ujmMEYNSfxBLahUczEPr1SlRcmI3uEZRLY8vktWn9B7o_8f0kOmn2rX4Ff28jXhoE_ATCfqtk
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+8th+lung+cancer+TNM+classification+and+clinical+staging+system%3A+review+of+the+changes+and+clinical+implications&rft.jtitle=Quantitative+imaging+in+medicine+and+surgery&rft.au=Lim%2C+Wanyin&rft.au=Ridge%2C+Carole+A&rft.au=Nicholson%2C+Andrew+G&rft.au=Mirsadraee%2C+Saeed&rft.date=2018-08-01&rft.issn=2223-4292&rft.volume=8&rft.issue=7&rft.spage=709&rft_id=info:doi/10.21037%2Fqims.2018.08.02&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2223-4292&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2223-4292&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2223-4292&client=summon